Rescheduling

Cannabis Rescheduling

Cannabis rescheduling is the formal administrative process by which the DEA and HHS reclassify cannabis under the Controlled Substances Act. In August 2023, HHS recommended moving cannabis from Schedule I to Schedule III. The DEA published a Notice of Proposed Rulemaking in May 2024 proposing Schedule III classification.

Schedule I to Schedule III

Moving cannabis from Schedule I to Schedule III would have three primary effects:

1. Section 280E eliminated — cannabis businesses could deduct ordinary business expenses, dramatically reducing effective tax rates
2. Research expanded — fewer regulatory barriers to clinical cannabis research
3. FDA authority — FDA may assert greater oversight over cannabis products

What Rescheduling Does Not Do

Rescheduling does not legalize adult-use cannabis, allow interstate commerce, resolve banking (which requires SAFE Banking Act), or automatically change state laws. It is a partial reform, not full federal legalization.

Timeline

After the NPRM, there will be a public comment period, potential administrative law hearings, and a final DEA rule. Legal challenges are expected. The process is likely to take 1–3 years from the 2024 proposed rule.

Business Planning Implications

Operators should model their financials under both a 280E and a post-280E scenario. Capital allocation, debt structure, and M&A valuations will all shift materially if rescheduling is finalized.

Work With Hoban

[Schedule a consultation](/consultation?source=glossary&term=rescheduling) to plan for rescheduling's business impacts.